Tuesday, October 29, 2013
Sysmex, National Cancer Center In Diagnostic Drug Partnership
TOKYO (Nikkei)--Sysmex Corp. (6869) and the National Cancer Center on Monday announced a comprehensive partnership to jointly develop cancer diagnostic drugs.
The aim of the partnership is to have Sysmex commercialize analysis technology and biomarkers discovered by the National Cancer Center that can predict the efficacy and side effects of anti-cancer drugs. They hope to first commercialize a biomarker that can predict the efficacy of drugs used to treat malignant bone tumors.
The two may also conduct joint research and have the National Cancer Center evaluate diagnostic drugs developed by Sysmex.
The collaboration is intended to help advance individualized medicine, in which treatment regimens are determined in accordance with an individual patient's physical constitution, and popularize diagnostic drugs developed in Japan.
(The Nikkei, Oct. 29 morning edition)